Sanofi-Aventis To Expand China’s Flu Vaccine Market
This article was originally published in PharmAsia News
Executive Summary
Once its Shenzhen flu vaccine production plant goes into operation in 2012, Sanofi-Aventis plans to sell 15 million doses of seasonal flu vaccine annually in China. A company official reveals that the estimate is based on projected global need of 1.3 billion vaccine doses by 2016, with China being one of the major markets. However, the country's inoculation rate stands at a mere 1.5 percent compared with 20 to 40 percent in Europe and North America. Moreover, over 60 percent of China's users opt for low-cost domestic products. Sanofi thus needs to decrease its production cost. Analysts note that without a consortium to standardize vaccine production and management locally, replicated and wasted efforts are hampering promotion and widespread usage. (Click here for more - Chinese Language)
You may also be interested in...
Sanofi Pasteur To Produce Influenza A (H1N1) Vaccine In Shenzhen By 2012
Sanofi Pasteur is intensifying efforts to build a vaccine production base in Shenzhen (PharmAsia News, Oct. 20, 2008). The first phase of construction on the facility was completed in October 2008, and the entire project is scheduled to be completed by 2012. The facility will produce mainly influenza vaccines for influenza A and B type H1N1 and H3N2, with an annual output for 25 million people. To facilitate the project, Shenzhen municipal government will handle all issues of certification and licenses as well as business consulting by the end of December. (Click here for more - Chinese Language)
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.